Trials / Completed
CompletedNCT02961660
A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir
An Open-label Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of odalasvir (ODV) in participants with severe renal impairment and compare with the PK in matched participants with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Odalasvir | Participants will receive odalasvir 25 mg tablet, orally. |
Timeline
- Start date
- 2016-11-09
- Primary completion
- 2018-04-09
- Completion
- 2018-04-09
- First posted
- 2016-11-11
- Last updated
- 2025-02-03
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02961660. Inclusion in this directory is not an endorsement.